医学
地氯雷他定
丙酸氟替卡松
氮芥
糠酸莫米松
生活质量(医疗保健)
随机对照试验
变应原免疫治疗
鼻腔给药
氯雷他定
哮喘
过敏原
过敏
内科学
药理学
皮质类固醇
免疫学
护理部
作者
Ludger Klimek,Pascal Demoly,David Price
标识
DOI:10.1586/17512433.2016.1148598
摘要
For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and omalizumab. A novel intranasal formulation of azelastine hydrochloride and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines.
科研通智能强力驱动
Strongly Powered by AbleSci AI